72F fusion protein vaccine

72F fusion protein vaccine is a candidate tuberculosis vaccine created by Statens Serum Institut (SSI). The 72F fusion protein is composed of the Rv0125 and Rv1196 proteins derived from Mycobacterium tuberculosis. Phase I clinical trials were completed in 2005 and Phase II trials are awaited.

See also

• Fusion protein

References

• Kaufmann SHE, McMichael AJ (2005). "Annulling a dangerous liaison: vaccination strategies against AIDS and tuberculosis". Nature Medicine. 11 (4 suppl): S33–S44. doi:10.1038/nm1221. PMC 7095892 . PMID 15812488.

This article "72F fusion protein vaccine" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:72F fusion protein vaccine. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.

📰 Article(s) of the same category(ies)

• Neuro-Immune Dysfunction Syndrome
• Oragen

---